Prelude Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.31
- Today's High:
- $3.57
- Open Price:
- $3.49
- 52W Low:
- $3.17
- 52W High:
- $8.665
- Prev. Close:
- $3.5
- Volume:
- 44629
Company Statistics
- Market Cap.:
- $200.60 million
- Book Value:
- 4.788
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.02%
- Return on Equity TTM:
- -46.43%
Company Profile
Prelude Therapeutics Inc had its IPO on 2020-09-25 under the ticker symbol PRLD.
The company operates in the Healthcare sector and Biotechnology industry. Prelude Therapeutics Inc has a staff strength of 122 employees.
Stock update
Shares of Prelude Therapeutics Inc opened at $3.49 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.31 - $3.57, and closed at $3.32.
This is a -5.14% slip from the previous day's closing price.
A total volume of 44,629 shares were traded at the close of the day’s session.
In the last one week, shares of Prelude Therapeutics Inc have slipped by -9.29%.
Prelude Therapeutics Inc's Key Ratios
Prelude Therapeutics Inc has a market cap of $200.60 million, indicating a price to book ratio of 1.1447 and a price to sales ratio of 0.
In the last 12-months Prelude Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-124046000. The EBITDA ratio measures Prelude Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Prelude Therapeutics Inc’s operating margin was 0% while its return on assets stood at -29.02% with a return of equity of -46.43%.
In Q2, Prelude Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Prelude Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Prelude Therapeutics Inc’s profitability.
Prelude Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.2145. Its price to sales ratio in the trailing 12-months stood at 0.
Prelude Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $280.61 million
- Total Liabilities
- $15.19 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $983000
- Dividend Payout Ratio
- 0%
Prelude Therapeutics Inc ended 2024 with $280.61 million in total assets and $0 in total liabilities. Its intangible assets were valued at $280.61 million while shareholder equity stood at $262.06 million.
Prelude Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $15.19 million in other current liabilities, 5000.00 in common stock, $-392707000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $26.45 million and cash and short-term investments were $254.99 million. The company’s total short-term debt was $938,000 while long-term debt stood at $0.
Prelude Therapeutics Inc’s total current assets stands at $260.21 million while long-term investments were $0 and short-term investments were $228.54 million. Its net receivables were $0 compared to accounts payable of $5.59 million and inventory worth $0.
In 2024, Prelude Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $983000.
Comparatively, Prelude Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.32
- 52-Week High
- $8.665
- 52-Week Low
- $3.17
- Analyst Target Price
- $10.75
Prelude Therapeutics Inc stock is currently trading at $3.32 per share. It touched a 52-week high of $8.665 and a 52-week low of $8.665. Analysts tracking the stock have a 12-month average target price of $10.75.
Its 50-day moving average was $3.95 and 200-day moving average was $5.46 The short ratio stood at 22.4 indicating a short percent outstanding of 0%.
Around 916.5% of the company’s stock are held by insiders while 8433.7% are held by institutions.
Frequently Asked Questions About Prelude Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.